Softgel Source, LLC announced a new program for rapid turnaround of low-volume, custom ingestible softgels, offering production priority and no minimum order quantity to facilitate product testing. The initiative aims to support U.S. companies in bringing manufacturing back home and strengthening their competitive position in the marketplace. Kevin McDowell, Founder and CEO of Softgel Source, stated that U.S. companies face both challenges and opportunities in domestic manufacturing. The company's Portland location positions it to help biotech and pharmaceutical businesses rapidly develop and test new softgel products.
This expansion reflects broader trends in U.S. manufacturing, with Deloitte and The Manufacturing Institute projecting continued job growth and biotech manufacturing expected to grow 6–8% annually through 2030. Businesses dependent on offshore manufacturing increasingly face disrupted supply chains, long lead times, and shifting tariffs. McDowell emphasized that manufacturers investing in domestic product development will be best positioned to thrive. Softgel Source helps companies address these issues by offering U.S.-manufactured softgels with fast turnaround rates, serving as both a primary development partner and backup production source when offshore suppliers falter.
The program also addresses regulatory challenges, as constant changes in U.S. and international regulations require companies to reformulate and retest products on short notice. McDowell noted that a local U.S. manufacturer with fast turnaround and low minimum order quantities is ideal for time-sensitive reformulation and testing requirements. More information about the company's services is available at https://softgelsource.com.
Softgel Source focuses on custom softgel manufacturing for vitamin, medication, supplement, and pet product industries, specializing in responsive, rapid turnaround of prototype production and low-to-moderate volume manufacturing for U.S.-based clients. The company's approach supports the growing movement toward domestic manufacturing resilience and regulatory compliance in the ingestible products sector. This announcement matters because it represents a strategic response to critical vulnerabilities in global supply chains that have been exposed in recent years, particularly for essential products like pharmaceuticals and supplements. By eliminating minimum order requirements and prioritizing rapid production, Softgel Source lowers barriers for companies seeking to test and develop products domestically, which could accelerate innovation while reducing dependency on overseas manufacturing. The timing aligns with broader economic trends favoring reshoring and nearshoring as companies seek greater control over their supply chains amid geopolitical uncertainties and trade disruptions. Furthermore, the program addresses specific pain points in regulated industries where frequent formula adjustments are necessary to comply with evolving standards, making domestic manufacturing not just a strategic advantage but a practical necessity for maintaining market access. For U.S. businesses in the biotech and supplement sectors, this initiative provides a tangible pathway to build more resilient operations while potentially creating domestic jobs in alignment with projected industry growth. The implications extend beyond individual companies to potentially strengthen the overall competitiveness of U.S. manufacturing in high-value sectors where speed-to-market and regulatory agility are increasingly critical differentiators.
